Cognition and autonomic function in schizophrenia: Inferior cognitive test performance in electrodermal and niacin skin flush non-responders

European Psychiatry

Volumn 30, Issue 1, 2015, Pages 8-13

  Nilsson, B M ^a   Holm, G ^a   Hultman, C M ^b   Ekselius, L ^a  

^a UPPSALA UNIVERSITY   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Autonomic function; Cognition; Electrodermal activity; Niacin flush; Psychophysiology; Schizophrenia

Indexed keywords

NICOTINIC ACID; VASODILATOR AGENT;

ADULT; ARTICLE; AUTONOMIC NERVOUS SYSTEM FUNCTION; BENTON VISUAL RETENTION TEST; CLINICAL ARTICLE; COGNITION; COGNITIVE DEFECT; CONTROLLED STUDY; ELECTRODERMAL RESPONSE; EXECUTIVE FUNCTION; FEMALE; FINGERTAPPING TEST; FLUSHING; HUMAN; INTELLIGENCE QUOTIENT; MALE; PRIORITY JOURNAL; PSYCHOLOGIC TEST; PSYCHOMOTOR ACTIVITY; REY AUDITORY VERBAL LEARNING TEST; SCHIZOPHRENIA; TASK PERFORMANCE; VERBAL FLUENCY; WECHSLER INTELLIGENCE SCALE; WISCONSIN CARD SORTING TEST; NEUROPSYCHOLOGICAL TEST; PATHOPHYSIOLOGY; PSYCHOLOGICAL RATING SCALE; PSYCHOLOGY; SWEDEN;

ADULT; COGNITION; COGNITION DISORDERS; FEMALE; GALVANIC SKIN RESPONSE; HUMANS; MALE; NEUROPSYCHOLOGICAL TESTS; NIACIN; PSYCHIATRIC STATUS RATING SCALES; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; SWEDEN; VASODILATOR AGENTS;

EID: 84920944218     PISSN: 09249338     EISSN: 17783585     Source Type: Journal    
DOI: 10.1016/j.eurpsy.2014.06.004     Document Type: Article

References (53)

1. Bar K.J., Letzsch A., Jochum T., Wagner G., Greiner W., Sauer H. Loss of efferent vagal activity in acute schizophrenia. J Psychiatr Res 2005, 39:519-527.
2. Boden R., Lindstrom L., Rautaharju P., Sundstrom J. Electrocardiographic signs of autonomic imbalance in medicated patients with first-episode schizophrenia spectrum disorders--relations to first treatment discontinuation and five-year remission status. Eur Psychiatry 2012, 27:213-218.
3. Bosveld-van Haandel L., Knegtering R., Kluiter H., van den Bosch R.J. Niacin skin flushing in schizophrenic and depressed patients and healthy controls. Psychiatry Res 2006, 143:303-306.
4. Brekke J.S., Raine A., Ansel M., Lencz T., Bird L. Neuropsychological and psychophysiological correlates of psychosocial functioning in schizophrenia. Schizophr Bull 1997, 23:19-28.
5. Brekke J.S., Raine A., Thomson C. Cognitive and psychophysiological correlates of positive, negative, and disorganized symptoms in the schizophrenia spectrum. Psychiatry Res 1995, 57:241-250.
6. Chang S.S., Liu C.M., Lin S.H., Hwu H.G., Hwang T.J., Liu S.K., et al. Impaired flush response to niacin skin patch among schizophrenia patients and their nonpsychotic relatives: the effect of genetic loading. Schizophr Bull 2009, 35:213-221.
7. Chouinard G., Margolese H.C. Manual for the Extrapyramidal Symptom Rating Scale (ESRS). Schizophr Res 2005, 76:247-265.
8. Dawson M.E., Nuechterlein K.H. Psychophysiological dysfunctions in the developmental course of schizophrenic disorders. Schizophr Bull 1984, 10:204-232.
9. Dawson M.E., Nuechterlein K.H., Schell A.M., Gitlin M., Ventura J. Autonomic abnormalities in schizophrenia. State or trait indicators?. Arch Gen Psychiatry 1994, 51:813-824.
10. Dawson M.E., Schell A.M. What does electrodermal activity tell us about prognosis in the schizophrenia spectrum?. Schizophr Res 2002, 54:87-93.
11. Drummond P.D., Lance J.W. Facial flushing and sweating mediated by the sympathetic nervous system. Brain 1987, 110(Pt 3):793-803.
12. Drummond P.D., Lazaroo D. The effect of niacin on facial blood flow in people with an elevated fear of negative evaluation. Eur Neuropsychopharmacol 2012, 22:200-204.
13. Fuentes I., Garcia Merita M., Miquel M., Rojo J. Relationships between electrodermal activity and symptomatology in schizophrenia. Psychopathology 1993, 26:47-52.
14. Glen A.I., Cooper S.J., Rybakowski J., Vaddadi K., Brayshaw N., Horrobin D.F. Membrane fatty acids, niacin flushing and clinical parameters. Prostaglandins Leukot Essent Fatty Acids 1996, 55:9-15.
15. Gruzelier J.H., Venables P.H. Skin conductance orienting activity in a heterogeneous sample of schizophrenics. J Nerv Ment Dis 1972, 155:277-287.
16. Horrobin D.F., Glen A.I., Vaddadi K. The membrane hypothesis of schizophrenia. Schizophr Res 1994, 13:195-207.
17. Hudson C.J., Lin A., Cogan S., Cashman F., Warsh J.J. The niacin challenge test: clinical manifestation of altered transmembrane signal transduction in schizophrenia?. Biol Psychiatry 1997, 41:507-513.
18. Hultman C.M., Ohlund L.S., Wieselgren I.M., Ohman A., Ost L.G. Electrodermal activity and social network as predictors of outcome of episodes in schizophrenia. J. Abnorm Psychol 1996, 105:626-636.
19. Ikezawa S., Corbera S., Liu J., Wexler B.E. Empathy in electrodermal responsive and nonresponsive patients with schizophrenia. Schizophr Res 2012, 142:71-76.
20. Israel A.K., Seeck A., Boettger M.K., Rachow T., Berger S., Voss A., et al. Peripheral endothelial dysfunction in patients suffering from acute schizophrenia: a potential marker for cardiovascular morbidity?. Schizophr Res 2011, 128:44-50.
21. Kamanna V.S., Ganji S.H., Kashyap M.L. The mechanism and mitigation of niacin-induced flushing. Int J Clin Pract 2009, 63:1369-1377.
22. Kay S.R., Fiszbein A., Opler L.A. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987, 13:261-276.
23. Kim D.K., Shin Y.M., Kim C.E., Cho H.S., Kim Y.S. Electrodermal responsiveness, clinical variables, and brain imaging in male chronic schizophrenics. Biol Psychiatry 1993, 33:786-793.
24. Levinson D.F., Edelberg R. Scoring criteria for response latency and habituation in electrodermal research: a critique. Psychophysiology 1985, 22:417-426.
25. Lezak M.D. Neuropsychological assessment 1995, Oxford University Press, New York. Third edition.
26. Lin S.H., Liu C.M., Chang S.S., Hwu H.G., Liu S.K., Hwang T.J., et al. Familial aggregation in skin flush response to niacin patch among schizophrenic patients and their nonpsychotic relatives. Schizophr Bull 2007, 33:174-182.
27. Lindstrom L.H. Clinical and biological markers for outcome in schizophrenia: a review of a longitudinal follow-up study in Uppsala schizophrenia research project. Neuropsychopharmacology 1996, 14:23S-26S.
28. Liu C.M., Chang S.S., Liao S.C., Hwang T.J., Shieh M.H., Liu S.K., et al. Absent response to niacin skin patch is specific to schizophrenia and independent of smoking. Psychiatry Res 2007, 152:181-187.
29. Lysaker P.H., Bryson G.J., Lancaster R.S., Evans J.D., Bell M.D. Insight in schizophrenia: associations with executive function and coping style. Schizophr Res 2003, 59:41-47.
30. Mathewson K.J., Jetha M.K., Goldberg J.O., Schmidt L.A. Autonomic regulation predicts performance on Wisconsin Card Sorting Test (WCST) in adults with schizophrenia. Biol Psychol 2012, 91:389-399.
31. Messamore E. Niacin subsensitivity is associated with functional impairment in schizophrenia. Schizophr Res 2012, 137:180-184.
32. Messamore E., Hoffman W.F., Janowsky A. The niacin skin flush abnormality in schizophrenia: a quantitative dose-response study. Schizophr Res 2003, 62:251-258.
33. Messamore E., Hoffman W.F., Yao J.K. Niacin sensitivity and the arachidonic acid pathway in schizophrenia. Schizophr Res 2010, 122:248-256.
34. Montgomery P., Burton J.R., Sewell R.P., Spreckelsen T.F., Richardson A.J. Low blood long chain omega-3 fatty acids in UK children are associated with poor cognitive performance and behavior: a cross-sectional analysis from the DOLAB study. PLoS ONE 2013, 8:e66697.
35. Morrow J.D., Parsons W.G., Roberts L.J. Release of markedly increased quantities of prostaglandin D2 in vivo in humans following the administration of nicotinic acid. Prostaglandins 1989, 38:263-274.
36. Nadalin S., Giacometti J., Jonovska S., Tomljanovic D., Buretic-Tomljanovic A. The impact of PLA2G4A and PTGS2 gene polymorphisms, and red blood cell PUFAs deficit on niacin skin flush response in schizophrenia patients. Prostaglandins Leukot Essent Fatty Acids 2013, 88:185-190.
37. Nilsson B.M., Hultman C.M., Ekselius L. Test-retest stability of the oral niacin test and electrodermal activity in patients with schizophrenia. Prostaglandins Leukot Essent Fatty Acids 2009, 81:367-372.
38. Nilsson B.M., Hultman C.M., Wiesel F.A. Niacin skin-flush response and electrodermal activity in patients with schizophrenia and healthy controls. Prostaglandins Leukot Essent Fatty Acids 2006, 74:339-346.
39. Ohman A. Electrodermal activity and vulnerability to schizophrenia: a review. Biol Psychol 1981, 12:87-145.
40. Ohman A., Ohlund L.S., Alm T., Wieselgren I.M., Ost L.G., Lindstrom L.H. Electrodermal nonresponding, premorbid adjustment, and symptomatology as predictors of long-term social functioning in schizophrenics. J Abnorm Psychol 1989, 98:426-435.
41. Parson H.K., Harati H., Cooper D., Vinik A.I. The role of prostaglandin D2 and the autonomic nervous system on niacin induced flushing. J Diabetes 2012.
42. Puri B.K., Easton T., Das I., Kidane L., Richardson A.J. The niacin skin flush test in schizophrenia: a replication study. Int J Clin Pract 2001, 55:368-370.
43. Ross B.M., Hughes B., Turenne S., Seeman M., Warsh J.J. Reduced vasodilatory response to methylnicotinate in schizophrenia as assessed by laser Doppler flowmetry. Eur Neuropsychopharmacol 2004, 14:191-197.
44. Schaefer J., Giangrande E., Weinberger D.R., Dickinson D. The global cognitive impairment in schizophrenia: consistent over decades and around the world. Schizophr Res 2013, 150:42-50.
45. Schell A.M., Dawson M.E., Nuechterlein K.H., Subotnik K.L., Ventura J. The temporal stability of electrodermal variables over a one-year period in patients with recent-onset schizophrenia and in normal subjects. Psychophysiology 2002, 39:124-132.
46. Schell A.M., Dawson M.E., Rissling A., Ventura J., Subotnik K.L., Gitlin M.J., et al. Electrodermal predictors of functional outcome and negative symptoms in schizophrenia. Psychophysiology 2005, 42:483-492.
47. Shah S.H., Vankar G.K., Peet M., Ramchand C.N. Unmedicated schizophrenic patients have a reduced skin flush in response to topical niacin. Schizophr Res 2000, 43:163-164.
48. Smesny S., Berger G., Rosburg T., Riemann S., Riehemann S., McGorry P., et al. Potential use of the topical niacin skin test in early psychosis -- a combined approach using optical reflection spectroscopy and a descriptive rating scale. J Psychiatr Res 2003, 37:237-247.
49. Smesny S., Rosburg T., Riemann S., Baur K., Rudolph N., Berger G., et al. Impaired niacin sensitivity in acute first-episode but not in multi-episode schizophrenia. Prostaglandins Leukot Essent Fatty Acids 2005, 72:393-402.
50. Strauss J.S., Carpenter W.T. The prediction of outcome in schizophrenia. I. Characteristics of outcome. Arch Gen Psychiatry 1972, 27:739-746.
51. Tavares H., Yacubian J., Talib L.L., Barbosa N.R., Gattaz W.F. Increased phospholipase A2 activity in schizophrenia with absent response to niacin. Schizophr Res 2003, 61:1-6.
52. Ward P.E., Sutherland J., Glen E.M., Glen A.I. Niacin skin flush in schizophrenia: a preliminary report. Schizophr Res 1998, 29:269-274.
53. Weinberger D.R. Implications of normal brain development for the pathogenesis of schizophrenia. Arch Gen Psychiatry 1987, 44:660-669.